Physician
Oncology
Dr. Partow Kebriaei, MD
|
|
Give Review
Dr. Partow Kebriaei works in the field of Oncology. She studied medicine at University of Texas Southwestern Medical School. Partow Kebriaei is a published doctor and has 100 publications published. The lastest was: 'Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia.' She accepts all Medicare patients.
Publications
- Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia.
- Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
- Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
- Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with Acute lymphoblastic leukaemia.
- Enforced fucosylation of cord blood hematopoietic Cells accelerates neutrophil and platelet engraftment after transplantation.
- Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hemato...
- Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem Cell transplantation for relapsed myeloma.
- Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-Cell-depleted or unmodified allografts.
- Comprehensive craniospinal radiation for controlling central nervous system Leukemia.
- Can a Female Donor for a Male Recipient Decrease Relapse Rate for Patients with AML Treated with Allogeneic Hematopoietic Stem Cell Transplantation?
- Vaccination guidelines after hematopoietic stem Cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice.
- Progress in Novel Cellular Therapy Options for Chronic Lymphocytic Leukemia: The MD Anderson Perspective.
- Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unre...
- Short-term cardiac toxicity of autologous hematopoietic stem Cell transplant for multiple myeloma.
- Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
- Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation.
- Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
- Is there an expiration date for a cord blood unit in storage?
- The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.
- Low rate of infusional toxicity after expanded cord blood transplantation.
- Alopecia areata after HLA-identical BMT from an affected, sibling donor.
- The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
- A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T Cells to target CD19.
- The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem Cell transplantation.
- Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor Cell mobilization.
- Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhi...
- Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
- Toward eliminating HLA class I expression to generate universal Cells from allogeneic donors.
- A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients w...
- Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed Acute lymphocytic leukemia.
- Outcomes of adults with Acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT).
- Multicenter study of banked third party virus-specific T-Cells to treat severe viral infections after hematopoietic stem Cell transplantation.
- High-dose chemotherapy and Autologous Stem Cell Transplantation For Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).
- Dose intensification of Busulfan in the preparative regimen is associated with improved survival: A Phase I/II Controlled, Randomized Study.
- Clinical application of sleeping beauty and artificial antigen presenting Cells to genetically modify T Cells from peripheral and umbilical cord blood.
- Sleeping beauty system to redirect T-Cell specificity for human applications.
- Incidence and natural history of pure red Cell aplasia in major ABO-mismatched haematopoietic Cell transplantation.
- Cord-blood engraftment with ex vivo mesenchymal-Cell coculture.
- CARs in Chronic Lymphocytic Leukemia - Ready to Drive.
- Prognostic significance of 11q23 aberrations in adult Acute myeloid leukemia and the role of allogeneic stem cell transplantation.
- Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome.
- High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-Cell transplantation in patients with refractory lymphoid malignancies.
- Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with Acute lymphoblastic leukemia.
- Bayesian continual reassessment method for dose-finding trials infusing T Cells with limited sample size.
- Significance of Persistent Cytogenetic Abnormalities at Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission.
- Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplant.
- Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell...
- Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL.
- Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular Lymphoma: 12-year results.
- A foundation for "universal" T-Cell based immunotherapy: T-Cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous...
- Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Ty...
- A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem Cells in patients with non-Ho...
- Chimeric antibody receptors (CARs): Driving T-Cell specificity to enhance anti-tumor immunity.
- Allogeneic stem cell transplantation for chronic myeloid Leukemia resistant to tyrosine kinase inhibitors.
- High incidence of vitamin D deficiency in patients undergoing allogeneic stem Cell transplantation.
- Treatment of FLT3-ITD-positive Acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
- Evaluation and management of BK virus-associated nephropathy following allogeneic hematopoietic Cell transplantation.
- Platelet Recovery Prior to Allogeneic Stem Cell Transplant Predicts Posttransplant Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
- Reprogramming CD19-specific T Cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.
- Persistence of cytogenetic abnormalities at complete remission after induction in patients with Acute myeloid leukemia: prognostic significance and the potential role ...
- Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.
- Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with Acute myeloid leukemia or myelodysplastic ...
- Treatment of graft-versus-host-disease with mesenchymal stromal Cells.
- MSCs in hematopoietic Cell transplantation.
- Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous Leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1...
- Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared with One Human Le...
- Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid Leukemia and MDS.
- Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem Cell transplantation in patients with advanced lympho...
- A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T Cells.
- First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) Acute lymphoblastic leuk...
- Modern treatment programs for adults with Acute lymphoblastic leukemia.
- Combining CD19 redirection and alloanergization to generate tumor-specific human T Cells for allogeneic Cell therapy of B-Cell malignancies.
- Reduced-intensity allogeneic hematopoietic stem Cell transplantation for relapsed multiple myeloma.
- piggyBac transposon/transposase system to generate CD19-specific T Cells for the treatment of B-lineage malignancies.
- Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous Leukemia in the imatinib era.
- Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
- Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of Acute graft-versus-host disease.
- Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of Acute graft-versus-host disease.
- Endpoints for clinical trials testing treatment of Acute graft-versus-host disease: a joint statement.
- Impairment of filgrastim-induced stem Cell mobilization after prior lenalidomide in patients with multiple myeloma.
- Poor hematopoietic stem Cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma.
- Low-dose azacitidine after allogeneic stem cell transplantation for Acute leukemia.
- Feasibility of allo-SCT after hypomethylating therapy with decitabine for Myelodysplastic syndrome.
- Therapy-related Acute myelogenous leukemia and myelodysplastic syndrome in patients with Acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphami...
- Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-Cell lymphoma treated with...
- Secondary myelodysplastic syndrome in a patient with Philadelphia-positive Acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus ...
- Successful autologous stem cell collection in patients with chronic myeloid Leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL express...
- High-dose chemotherapy and autologous hematopoietic progenitor Cell transplantation for non-Hodgkin''s lymphoma in patients >65 years of age.
- Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem Cell transplantation for high-risk CD33 positive myeloid le...
- Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in Myeloma patients undergoing an autotransplant.
- Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid Leukemia.
- Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem Cell transplantation.
- Biphenotypic Acute leukaemia: a case series.
- Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid Leukemia: no evidence for increased transplant-rel...
- Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk Acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity condi...
- Autologous stem Cell transplantation is safe and feasible in elderly patients with multiple myeloma.
- Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for Acute lymphoblastic leukemia.
- Fixed-dose single agent pegfilgrastim for peripheral blood progenitor Cell mobilisation in patients with multiple myeloma.
- Cytokines in the treatment of Acute leukemias.
Schools
U Of Tx Med Sch At Houston
University Tx Sw Med Center
University Chicago Med Center
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Basal Cell Carcinoma
- Breast Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Chicago -
University of Texas Southwestern Medical School -
University of Texas Medical School
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1689768475 | |
| NPPES Provider LastName | KEBRIAEI | |
| NPPES Provider FirstName | PARTOW | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology | |
| Total Claim Count | 320.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 16.0 | |
| Percent Opioid Claims | 5.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1689768475 |
| Last Name Of The Provider | KEBRIAEI |
| First Name Of The Provider | PARTOW |
| View All |
Similar Doctors
|
|
Dr. Saraswati P. Reddy, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Francisco J. Esteva, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tejash R. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jay B. Shah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ralph G. Zinner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jatin Shah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan M. Kurie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mothaffar F. Rimawi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristy L. Richards, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Waun K. Hong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Srdan Verstovsek, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Uzma Iqbal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amanda L. Olson, MD |
|
|
Dr. Jennifer K. Litton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Faye M. Johnson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey J. Molldrem, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|